Dr. Steven Gray received his BA and MSc at the Department of Genetics, Trinity College Dublin, Ireland. He subsequently obtained his PhD at the Karolinska Institute, Stockholm, Sweden. Following completion of his PhD, Dr. Gray travelled to the USA to continue his postgraduate studies at the Van Andel Research Institute (Michigan) and as a visiting scientist at Harvard Medical School (Boston), before returning to Europe to work at the German Cancer Research Centre (DKFZ, Heidelberg, Germany) and the Hagedorn Research Institute (Novo Nordisk, Copenhagen, Denmark). Throughout this period Dr. Gray has exclusively studied the role of epigenetics in disease, with a specific focus on the potential therapeutic role of histone deacetylase inhibitors in the treatment of neurodegeneration, diabetes and cancer.
Dr. Gray returned to Ireland in 2004 to work in the Thoracic Oncology unit. Dr. Gray currently heads a subsection within this unit which focuses on the role of epigenetics in malignancy.
Currently Dr. Gray works closely with Professor Stephen Finn on studies in prostate cancer involving the following: (a) The epigenetic mechanisms underpinning the development of resistance to therapy; (b) The potential utility of non-coding RNA repertoires as predictive/prognostic biomarkers for response to therapy; (c) The roles of circulating tumor cells and cancer stem cells in drug resistance and (d) the roles of epigenetic readers, writers and erasers in disease and as candidate therapeutic targets for the treatment of same.
Dr. Gray currently sits on the editorial boards of several journals including Clinical Epigenetics.